Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 4
1982 5
1983 11
1984 12
1985 15
1986 15
1987 30
1988 32
1989 27
1990 38
1991 29
1992 47
1993 32
1994 35
1995 41
1996 37
1997 34
1998 42
1999 62
2000 46
2001 49
2002 48
2003 60
2004 60
2005 54
2006 81
2007 69
2008 80
2009 86
2010 103
2011 104
2012 102
2013 108
2014 103
2015 98
2016 117
2017 92
2018 95
2019 104
2020 58
Text availability
Article attribute
Article type
Publication date

Search Results

2,109 results
Results by year
Filters applied: . Clear all
Page 1
Ulcerative colitis.
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ungaro R, et al. Lancet. 2017 Apr 29;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2. Epub 2016 Dec 1. Lancet. 2017. PMID: 27914657 Free PMC article. Review.
Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. ...Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppr …
Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal seg …
Ulcerative colitis.
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ordás I, et al. Lancet. 2012 Nov 3;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0. Epub 2012 Aug 20. Lancet. 2012. PMID: 22914296 Free article. Review.
Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with proctitis or left-sided
Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and gener
Ulcerative colitis: epidemiology, diagnosis, and management.
Feuerstein JD, Cheifetz AS. Feuerstein JD, et al. Mayo Clin Proc. 2014 Nov;89(11):1553-63. doi: 10.1016/j.mayocp.2014.07.002. Epub 2014 Sep 8. Mayo Clin Proc. 2014. PMID: 25199861 Review.
Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that starts in the rectum and extends proximally. ...In the right clinical setting, the diagnosis of ulcerative colitis is based prim
Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that st
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.
Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. Ko CW, et al. Gastroenterology. 2019 Feb;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009. Epub 2018 Dec 18. Gastroenterology. 2019. PMID: 30576644 Free PMC article. Review. No abstract available.
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
Singh S, Feuerstein JD, Binion DG, Tremaine WJ. Singh S, et al. Gastroenterology. 2019 Feb;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18. Gastroenterology. 2019. PMID: 30576642 Free PMC article. Review.
Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed by primary care physicians or gastroenterologists. ...Focused questions included the following: (1) comparative effectiveness and tolerabil …
Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed …
5-Aminosalicylic acid, a specific drug for ulcerative colitis.
Hauso Ø, Martinsen TC, Waldum H. Hauso Ø, et al. Scand J Gastroenterol. 2015 Aug;50(8):933-41. doi: 10.3109/00365521.2015.1018937. Epub 2015 Mar 2. Scand J Gastroenterol. 2015. PMID: 25733192 Review.
The active part of salazopyrin, the oldest drug in use in the treatment of ulcerative colitis, is 5-aminosalicylic acid (5-ASA). ...Side effects with 5-ASA are rare, and every patient with ulcerative colitis who tolerate this drug, …
The active part of salazopyrin, the oldest drug in use in the treatment of ulcerative colitis, is 5-aminosalicylic acid …
5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis.
Shimizu H, Arai K, Tang J, Hosoi K, Funayama R. Shimizu H, et al. Pediatr Int. 2017 May;59(5):583-587. doi: 10.1111/ped.13235. Epub 2017 Apr 12. Pediatr Int. 2017. PMID: 28063246
BACKGROUND: 5-Aminosalicylate (5-ASA) is widely used as the first-line drug for ulcerative colitis (UC). 5-ASA is mostly a safe and effective drug, but it can bring about exacerbation due to 5-ASA intolerance. 5-ASA intolera …
BACKGROUND: 5-Aminosalicylate (5-ASA) is widely used as the first-line drug for ulcerative colitis (UC). …
Ulcerative colitis: epidemiology, clinical features and associated factors with surgical treatment in a tertiary hospital in Mexico.
León-Rendón JL, Jiménez-Bobadilla B, López-Pérez RY, Gracida-Mancilla NI, Alarcón-Bernés L, Villanueva Herrero JA. León-Rendón JL, et al. Cir Cir. 2019;87(4):450-458. doi: 10.24875/CIRU.18000737. Cir Cir. 2019. PMID: 31264991 English.
BACKGROUND: An increase incidence of ulcerative colitis (UC) has been reported in Mexico. It is important to know the clinical features of patients with UC, their clinical course, need for surgical treatment and outcomes. ...Nineteen patients (31.8%) presented extra …
BACKGROUND: An increase incidence of ulcerative colitis (UC) has been reported in Mexico. It is important to know the clinical …
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Scaldaferri F, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A. Scaldaferri F, et al. World J Gastroenterol. 2016 Jun 28;22(24):5505-11. doi: 10.3748/wjg.v22.i24.5505. World J Gastroenterol. 2016. PMID: 27350728 Free PMC article. Review.
Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the "forgotten organ", Gut Microbiota. Several studies have been conducted to assess the
Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an inter
Oral or Topical 5-ASA in Ulcerative Colitis.
Hanauer SB. Hanauer SB. Dig Dis. 2016;34(1-2):122-4. doi: 10.1159/000443026. Epub 2016 Mar 16. Dig Dis. 2016. PMID: 26982709 Review.
Aminosalicylates (5-ASAs) are foundational therapies for patients with mild-moderate active ulcerative colitis (UC) and to maintain remissions. ...This review summarizes data on pharmacokinetics and applications of oral and topical 5-ASA therapies in a …
Aminosalicylates (5-ASAs) are foundational therapies for patients with mild-moderate active ulcerative colitis (UC) and …
2,109 results
Jump to page
Feedback